Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Anti-amyloid beta (Aβ) monoclonal antibody

& fda max: Withdrawn 2024

Use the filters below to narrow your results.

None (1)

Aduhelm (1)

Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1)

Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1)

Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

IV infusion every 4 weeks (1)

PET Aβ reduction over months (1)

Withdrawn (1)

~25 days (1)

100% (IV) (1)

Discontinued/withdrawn (1)

Withdrawn from US market January 2024 (1)

Showing below up to 1 result in range #1 to #1.

A

Aducanumab

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"